display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - HER2-positive
la/mBC - HER2 positive - 2nd Line (L2)
TKI anti HER1/EGFR and HER2/neu
lapatinib based treatment
lapatinib plus capecitabine WJOG6110B/ELTOP
lapatinib plus trastuzumab EGF104900

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons